OLMA
Olema Pharmaceuticals, Inc.
+0.37 (+3.80%)10.10USD277K成交股數884M市值–本益比(近四季)–股價營收比–營收年增(近四季)2026-11-09下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0.00 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 2 · 291K · 1 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 0.00 · 291K |
| 近 180 天 淨額 | −291K |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-24 | 07-27 | Harmon Cyrus | Director | S 公開市場賣出 | 12.5K | 11.71 | 146K | 703K | SEC |
| 2026-07-23 | 07-27 | Harmon Cyrus | Director | S 公開市場賣出 | 12.5K | 11.58 | 145K | 715K | SEC |
| 2026-03-04 | 03-05 | Mitchell Shawnte | CHIEF LEGAL OFFICER | M 選擇權執行 | 25.0K | 4.37 | 109K | 25.0K | SEC |
| 2026-03-04 | 03-05 | Mitchell Shawnte | CHIEF LEGAL OFFICER | S 公開市場賣出 | 24.8K | 24.25 | 601K | 233 | SEC |
| 2026-03-04 | 03-05 | Mitchell Shawnte | CHIEF LEGAL OFFICER | S 公開市場賣出 | 233 | 24.69 | 6K | 0 | SEC |
| 2026-03-03 | 03-05 | Mitchell Shawnte | CHIEF LEGAL OFFICER | M 選擇權執行 | 15.0K | 4.37 | 66K | 15.0K | SEC |
| 2026-03-03 | 03-05 | Mitchell Shawnte | CHIEF LEGAL OFFICER | S 公開市場賣出 | 15.0K | 23.01 | 345K | 0 | SEC |
| 2026-02-02 | 02-17 | Austin Sasha Lu | VP of Finance and Controller | A 獲配股票 | 11.7K | – | – | 16.2K | SEC |
| 2026-01-20 | 01-21 | Harmon Cyrus | Director | S 公開市場賣出 | 10.0K | 26.88 | 269K | 728K | SEC |
| 2026-01-15 | 01-15 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | S 公開市場賣出 | 100K | 28.73 | 2.9M | 140K | SEC |
| 2026-01-14 | 01-16 | Harmon Cyrus | Director | S 公開市場賣出 | 3.5K | 29.12 | 102K | 738K | SEC |
| 2026-01-14 | 01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | S 公開市場賣出 | 15.0K | 28.60 | 429K | 578K | SEC |
| 2026-01-14 | 01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | S 公開市場賣出 | 35.0K | 28.99 | 1.0M | 543K | SEC |
| 2026-01-14 | 01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | M 選擇權執行 | 50.0K | 4.87 | 244K | 593K | SEC |
| 2026-01-13 | 01-15 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | S 公開市場賣出 | 3.8K | 28.01 | 107K | 240K | SEC |
| 2026-01-13 | 01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | S 公開市場賣出 | 49.8K | 27.60 | 1.4M | 543K | SEC |
| 2026-01-13 | 01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | M 選擇權執行 | 50.0K | 4.87 | 244K | 593K | SEC |
| 2026-01-13 | 01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | S 公開市場賣出 | 200 | 28.49 | 6K | 543K | SEC |
| 2026-01-12 | 01-14 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | S 公開市場賣出 | 10.0K | 28.34 | 283K | 145K | SEC |
| 2025-12-26 | 12-30 | Bohen Sean | President and CEO | G 贈與 | 8.5K | – | – | 238K | SEC |
| 2025-12-23 | 12-23 | Zojwalla Naseem | Chief Medical Officer | S 公開市場賣出 | 99.5K | 27.66 | 2.8M | 4.5K | SEC |
| 2025-12-23 | 12-23 | Zojwalla Naseem | Chief Medical Officer | M 選擇權執行 | 50.0K | 7.02 | 351K | 104K | SEC |
| 2025-12-22 | 12-29 | Harmon Cyrus | Director | S 公開市場賣出 | 2.9K | 28.53 | 82K | 741K | SEC |
| 2025-12-22 | 12-23 | Zojwalla Naseem | Chief Medical Officer | M 選擇權執行 | 42.8K | 15.25 | 653K | 147K | SEC |
| 2025-12-22 | 12-23 | Zojwalla Naseem | Chief Medical Officer | S 公開市場賣出 | 100K | 28.04 | 2.8M | 54.0K | SEC |
| 2025-12-22 | 12-23 | Zojwalla Naseem | Chief Medical Officer | M 選擇權執行 | 7.2K | 7.02 | 50K | 154K | SEC |
| 2025-12-19 | 12-23 | CLARK IAN T | Director | S 公開市場賣出 | 41.8K | 30.48 | 1.3M | 0 | SEC |
| 2025-12-19 | 12-23 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | S 公開市場賣出 | 43.7K | 30.40 | 1.3M | 558K | SEC |
| 2025-12-19 | 12-23 | CLARK IAN T | Director | M 選擇權執行 | 21.5K | 7.84 | 169K | 253K | SEC |
| 2025-12-19 | 12-23 | CLARK IAN T | Director | S 公開市場賣出 | 193K | 29.71 | 5.7M | 41.8K | SEC |
| 2025-12-19 | 12-23 | CLARK IAN T | Director | S 公開市場賣出 | 29.9K | 28.83 | 862K | 235K | SEC |
| 2025-12-19 | 12-23 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | S 公開市場賣出 | 6.0K | 31.39 | 190K | 552K | SEC |
| 2025-12-19 | 12-23 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | S 公開市場賣出 | 1.2K | 28.08 | 34K | 602K | SEC |
| 2025-12-19 | 12-23 | CLARK IAN T | Director | M 選擇權執行 | 12.1K | 4.08 | 49K | 265K | SEC |
| 2025-12-19 | 12-23 | CLARK IAN T | Director | M 選擇權執行 | 21.5K | 3.61 | 78K | 231K | SEC |
| 2025-12-19 | 12-23 | CLARK IAN T | Director | M 選擇權執行 | 210K | 4.41 | 925K | 210K | SEC |
| 2025-12-19 | 12-23 | Zojwalla Naseem | Chief Medical Officer | S 公開市場賣出 | 12.9K | 28.93 | 374K | 104K | SEC |
| 2025-12-19 | 12-23 | Zojwalla Naseem | Chief Medical Officer | S 公開市場賣出 | 57.1K | 28.03 | 1.6M | 117K | SEC |
| 2025-12-19 | 12-23 | Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | G 贈與 | 9.0K | – | – | 543K | SEC |
| 2025-12-19 | 12-23 | Zojwalla Naseem | Chief Medical Officer | M 選擇權執行 | 40.0K | 15.25 | 610K | 174K | SEC |
| 2025-12-08 | 12-09 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | G 贈與 | 75.0K | – | – | 244K | SEC |
| 2025-11-26 | 12-01 | Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | G 贈與 | 225K | – | – | 319K | SEC |
| 2025-11-25 | 11-25 | RAPPAPORT ANDREW | Director | G 贈與 | 35.9K | – | – | 0 | SEC |
| 2025-11-21 | 11-25 | RAPPAPORT ANDREW | Director | M 選擇權執行 | 35.9K | 0.39 | 14K | 35.9K | SEC |
| 2025-09-18 | 09-18 | Harmon Cyrus | Director | S 公開市場賣出 | 3.1K | 8.32 | 26K | 117K | SEC |
| 2025-09-18 | 09-18 | Harmon Cyrus | Director | S 公開市場賣出 | 10.0K | 8.33 | 83K | 744K | SEC |
| 2025-09-16 | 09-18 | Harmon Cyrus | Director | S 公開市場賣出 | 10.0K | 8.04 | 80K | 754K | SEC |
| 2025-09-16 | 09-18 | Harmon Cyrus | Director | S 公開市場賣出 | 1.9K | 8.08 | 15K | 120K | SEC |
| 2025-01-10 | 01-14 | LAMPERT MARK N | Director,Other | D 處分 | 162K | – | – | 2.0M | SEC |
| 2025-01-10 | 01-14 | LAMPERT MARK N | Director,Other | D 處分 | 235K | – | – | 2.7M | SEC |
| 2025-01-10 | 01-14 | BIOTECHNOLOGY VALUE FUND II LP | Director,Other | D 處分 | 22.7K | – | – | 348K | SEC |
| 2025-01-10 | 01-14 | BIOTECHNOLOGY VALUE FUND II LP | Director,Other | D 處分 | 235K | – | – | 2.7M | SEC |
| 2025-01-10 | 01-14 | BVF INC/IL | Director,Other | D 處分 | 22.7K | – | – | 348K | SEC |
| 2025-01-10 | 01-14 | BVF INC/IL | Director,Other | D 處分 | 162K | – | – | 2.0M | SEC |
| 2025-01-10 | 01-14 | BVF INC/IL | Director,Other | D 處分 | 235K | – | – | 2.7M | SEC |
| 2025-01-10 | 01-14 | BVF PARTNERS L P/IL | Director,Other | D 處分 | 22.7K | – | – | 348K | SEC |
| 2025-01-10 | 01-14 | BVF PARTNERS L P/IL | Director,Other | D 處分 | 162K | – | – | 2.0M | SEC |
| 2025-01-10 | 01-14 | BIOTECHNOLOGY VALUE FUND II LP | Director,Other | D 處分 | 162K | – | – | 2.0M | SEC |
| 2025-01-10 | 01-14 | BVF PARTNERS L P/IL | Director,Other | D 處分 | 235K | – | – | 2.7M | SEC |
| 2025-01-10 | 01-14 | BIOTECHNOLOGY VALUE FUND L P | Director,Other | D 處分 | 22.7K | – | – | 348K | SEC |
| 2025-01-10 | 01-14 | BIOTECHNOLOGY VALUE FUND L P | Director,Other | D 處分 | 162K | – | – | 2.0M | SEC |
| 2025-01-10 | 01-14 | LAMPERT MARK N | Director,Other | D 處分 | 22.7K | – | – | 348K | SEC |
| 2025-01-10 | 01-14 | BIOTECHNOLOGY VALUE FUND L P | Director,Other | D 處分 | 235K | – | – | 2.7M | SEC |
| 2025-01-10 | 01-14 | BVF GP HOLDINGS LLC | Director,Other | D 處分 | 235K | – | – | 2.7M | SEC |
| 2025-01-10 | 01-14 | BVF GP HOLDINGS LLC | Director,Other | D 處分 | 162K | – | – | 2.0M | SEC |
| 2025-01-10 | 01-14 | BVF I GP LLC | Director,Other | D 處分 | 22.7K | – | – | 348K | SEC |
| 2025-01-10 | 01-14 | BVF II GP LLC | Director,Other | D 處分 | 162K | – | – | 2.0M | SEC |
| 2025-01-10 | 01-14 | BVF II GP LLC | Director,Other | D 處分 | 235K | – | – | 2.7M | SEC |
| 2025-01-10 | 01-14 | Biotechnology Value Trading Fund OS LP | Director,Other | D 處分 | 162K | – | – | 2.0M | SEC |
| 2025-01-10 | 01-14 | BVF I GP LLC | Director,Other | D 處分 | 162K | – | – | 2.0M | SEC |
| 2025-01-10 | 01-14 | BVF I GP LLC | Director,Other | D 處分 | 235K | – | – | 2.7M | SEC |
| 2025-01-10 | 01-14 | BVF Partners OS Ltd. | Director,Other | D 處分 | 22.7K | – | – | 348K | SEC |
| 2025-01-10 | 01-14 | BVF Partners OS Ltd. | Director,Other | D 處分 | 162K | – | – | 2.0M | SEC |
| 2025-01-10 | 01-14 | BVF II GP LLC | Director,Other | D 處分 | 22.7K | – | – | 348K | SEC |
| 2025-01-10 | 01-14 | BVF Partners OS Ltd. | Director,Other | D 處分 | 235K | – | – | 2.7M | SEC |
| 2025-01-10 | 01-14 | Biotechnology Value Trading Fund OS LP | Director,Other | D 處分 | 22.7K | – | – | 348K | SEC |
| 2025-01-10 | 01-14 | Biotechnology Value Trading Fund OS LP | Director,Other | D 處分 | 235K | – | – | 2.7M | SEC |
| 2025-01-10 | 01-14 | BVF GP HOLDINGS LLC | Director,Other | D 處分 | 22.7K | – | – | 348K | SEC |
| 2025-01-10 | 01-13 | Bain Capital Life Sciences Investors, LLC | TenPercentOwner | J 其他 | 3.5M | – | – | 4.3M | SEC |
| 2025-01-10 | 01-13 | Bain Capital Life Sciences IV General Partner, LLC | TenPercentOwner | J 其他 | 3.5M | – | – | 4.3M | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| FMR LLC | 12.1M | 152M | 新進 | 新進 |
| Paradigm Biocapital Advisors LP | 8.7M | 108M | 新進 | 新進 |
| Jupiter Topco LLC | 7.1M | 88.8M | 新進 | 新進 |
| Bain Capital Life Sciences Investors, LLC | 7.1M | 88.6M | 新進 | 新進 |
| BlackRock, Inc. | 6.7M | 84.0M | 新進 | 新進 |
| BVF INC/IL | 5.3M | 66.3M | 新進 | 新進 |
| Siren, L.L.C. | 4.9M | 60.8M | 新進 | 新進 |
| STATE STREET CORP | 4.3M | 54.0M | 新進 | 新進 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.3M | 41.8M | 新進 | 新進 |
| Logos Global Management LP | 3.2M | 40.1M | 新進 | 新進 |
| FRANKLIN RESOURCES INC | 2.3M | 29.4M | 新進 | 新進 |
| Cormorant Asset Management, LP | 2.1M | 26.9M | 新進 | 新進 |
| MORGAN STANLEY | 1.8M | 22.9M | 新進 | 新進 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8M | 22.8M | 新進 | 新進 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.7M | 20.8M | 新進 | 新進 |
| GOLDMAN SACHS GROUP INC | 1.6M | 19.6M | 新進 | 新進 |
| Deep Track Capital, LP | 1.5M | 18.8M | 新進 | 新進 |
| DIMENSIONAL FUND ADVISORS LP | 1.4M | 17.7M | 新進 | 新進 |
| LIGHTSPEED MANAGEMENT COMPANY, L.L.C. | 1.4M | 17.0M | 新進 | 新進 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 1.2M | 15.0M | 新進 | 新進 |
| Two Sigma TWO SIGMA INVESTMENTS, LP | 1.1M | 14.2M | 新進 | 新進 |
| Point72(柯恩) Point72 Asset Management, L.P. | 1.1M | 13.4M | 新進 | 新進 |
| Defilade Capital Management, L.P. | 925K | 11.6M | 新進 | 新進 |
| AMERIPRISE FINANCIAL INC | 841K | 10.5M | 新進 | 新進 |
| Woodline Partners LP | 751K | 9.4M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 185 -11 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 185 / 0 / 0 / 0 |
| 機構合計持股 · 佔流通股 | 102M · 100.0% |
| 合計季末市值 | 1.3B |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 15.7M |
|---|---|
| 與上期比 | -0.9% |
| 佔流通股數 | 17.90% |
| 日均成交量 | 845K |
| 回補天數 | 18.5 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 15.7M | -0.9% | 17.90% | 845K | 18.5 |
| 2026-08-14 | 15.8M | -1.0% | 18.07% | 1.1M | 14.3 |
| 2026-07-31 | 16.0M | +5.7% | 18.24% | 877K | 18.2 |
| 2026-07-15 | 15.1M | +7.6% | 17.26% | 1.3M | 11.3 |
| 2026-06-30 | 14.0M | +9.3% | 16.04% | 2.5M | 5.7 |
| 2026-06-15 | 12.8M | +7.7% | 14.68% | 1.6M | 7.9 |
| 2026-05-29 | 11.9M | +2.9% | 13.63% | 1.1M | 10.5 |
| 2026-05-15 | 11.6M | -11.2% | 13.24% | 1.1M | 10.2 |
| 2026-04-30 | 13.0M | +0.8% | 14.90% | 791K | 16.5 |
| 2026-04-15 | 12.9M | +5.5% | 14.78% | 888K | 14.6 |
| 2026-03-31 | 12.3M | +48.8% | 14.02% | 1.9M | 6.3 |
| 2026-03-13 | 8.2M | -0.2% | 9.42% | 2.8M | 3.0 |
| 2026-02-27 | 8.3M | -8.3% | 9.44% | 1.1M | 7.5 |
| 2026-02-13 | 9.0M | -11.0% | 10.29% | 1.6M | 5.7 |
| 2026-01-30 | 10.1M | +11.1% | 11.56% | 920K | 11.0 |
| 2026-01-15 | 9.1M | -12.5% | 10.40% | 1.5M | 6.3 |
| 2025-12-31 | 10.4M | -6.2% | 11.88% | 2.0M | 5.2 |
| 2025-12-15 | 11.1M | +2.6% | 12.68% | 3.2M | 3.5 |
| 2025-11-28 | 10.8M | +15.4% | 12.36% | 14.3M | 1.0 |
| 2025-11-14 | 9.4M | +11.9% | 10.70% | 941K | 10.0 |
| 2025-10-31 | 8.4M | +10.9% | 9.56% | 1.6M | 5.1 |
| 2025-10-15 | 7.5M | -3.1% | 8.62% | 1.2M | 6.3 |
| 2025-09-30 | 7.8M | -5.4% | 8.90% | 1.1M | 6.9 |
| 2025-09-15 | 8.2M | -2.1% | 9.42% | 1.8M | 4.7 |
| 2025-08-29 | 8.4M | -0.8% | 9.62% | 318K | 26.4 |
| 2025-08-15 | 8.5M | +11.1% | 9.69% | 587K | 14.4 |